Skip to main content
CellaVision logo

CellaVision — Investor Relations & Filings

Ticker · CEVI ISIN · SE0000683484 LEI · 529900IUBZBZ0HXFJ114 ST Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-04-11 Annual Report (ESEF)
Country SE Sweden
Listing ST CEVI

About CellaVision

https://www.cellavision.com/

CellaVision is a medical technology company that provides digital solutions for cell morphology in hematology. The company specializes in automating and standardizing the analysis of blood and other body fluids for both human and veterinary applications. Its core offerings include a complete system of analyzers, instruments, software, and reagents designed for hematology laboratories of all sizes. By utilizing patented technology that integrates automated microscopy, advanced image analysis, and artificial intelligence, CellaVision's systems digitize the traditional manual review of blood smears. This automation enhances laboratory workflow efficiency, improves diagnostic accuracy, and facilitates remote collaboration among healthcare professionals, advancing diagnostic certainty.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 1% confidence FY 2023
2024-04-11 Swedish
KALLELSE TILL ÅRSSTÄMMA i CELLAVISION AB (PUBL)
AGM Information Classification · 1% confidence The document is explicitly titled "KALLELSE TILL ÅRSSTÄMMA i CELLAVISION AB (PUBL)" which translates to "NOTICE OF ANNUAL GENERAL MEETING in CELLAVISION AB (PUBL)". It details the date, time, location, registration procedures, agenda items (including election of board members, auditors, and approval of remuneration report), and proposals for dividend distribution, all characteristic elements of a formal notice for an Annual General Meeting (AGM). This directly corresponds to the AGM Information category.
2024-04-02 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)". It details the date, time, location, procedures for participation (registration, proxy), and the proposed agenda items for the AGM, including elections for the Board and auditor, and resolutions on profit allocation and remuneration reports. This content directly corresponds to the materials distributed to shareholders in advance of an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2024-04-02 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive quarterly financial report for CellaVision, covering the period of October 1 to December 31, 2023. It includes detailed financial statements (income statement, cash flow, regional performance), management commentary (CEO's address), and analysis of business trends. It is not an announcement of a report (RPA) as it contains the actual substantive financial data and analysis. It is not a full 10-K as it focuses on a specific quarter (Q4) and the full year, fitting the definition of an Interim/Quarterly Report. Q4 2023
2024-02-07 Swedish
Earnings Release 2023
Earnings Release Classification · 1% confidence The document provides detailed financial results for the period October 1 – December 31, 2023, including key metrics like Net sales, EBITDA, Profit before tax, and Earnings per share, along with comparative figures for 2022. It also includes a CEO's comment, segment performance analysis (Americas, EMEA, APAC), and cash flow details. This structure, focusing on comprehensive financial performance for a specific period (Q4 2023), strongly indicates a periodic financial report. Since the period is quarterly (October 1 – December 31), it aligns best with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) as it covers only one quarter, nor is it just an Earnings Release (ER) as it contains extensive operational and financial detail beyond just highlights. The document length is substantial (47,421 chars), ruling out a simple Report Publication Announcement (RPA). Q4 2023
2024-02-07 English
CellaVision and Sysmex Sign Strategic Alliance Agreement
M&A Activity Classification · 1% confidence The document announces a 'Strategic Alliance Agreement' between CellaVision and Sysmex Corporation, detailing the expansion of their partnership until 2038. It includes quotes from executives and background information on both companies. Crucially, the final line states, 'This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation,' and it includes an attachment link. This structure—a brief announcement of a significant corporate event (a strategic agreement/partnership) that is legally required to be disclosed—fits best under the general 'Regulatory Filings' category (RNS), as it does not specifically match definitions for earnings (ER), capital changes (CAP), M&A (TAR), or management changes (MANG). Given the short length and the nature of announcing a legally mandated disclosure, RNS is the most appropriate general regulatory filing code.
2024-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.